Related Experiment Video
Updated: Mar 30, 2026
10:02
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
28.4K
Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease
Jeffrey T Apter1, Kuntal Shastri2, Katherine Pizano3
1Princeton Medical Institute, Global Clinical Trials, Global Medical Institute, LLC, Princeton University, Princeton, NJ USA.
Current Geriatrics Reports
|November 7, 2015
Summary
Alzheimer's disease (AD) is a growing health concern in the US and Western Europe. Research is intensifying to find ways to prevent and treat this neurodegenerative condition affecting the aging population.
Area of Science:
- Neuroscience
- Gerontology
- Public Health
Background:
- Alzheimer's disease (AD) represents a significant and escalating health challenge, particularly in the US and Western Europe.
- The aging Baby Boomer demographic is increasing the prevalence and public awareness of AD.
- Traditionally linked to aging, AD is now a prominent subject of scientific and public discourse.
Approach:
- Focus on modern research methodologies.
- Investigate preventative strategies for Alzheimer's disease.
- Explore therapeutic interventions for Alzheimer's disease.
Key Points:
- The increasing incidence of Alzheimer's disease necessitates urgent research.
- Understanding the link between aging and Alzheimer's is crucial.
- Public health initiatives are vital in addressing the growing burden of Alzheimer's disease.
Conclusions:
- Continued research is essential for managing the future impact of Alzheimer's disease.
- Preventative and treatment strategies are key to combating this neurodegenerative disorder.
- Alzheimer's disease poses a significant public health challenge for the coming decade.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:28Drug Therapy
401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
401
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
836
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
836